Only about 1% of newly developed drugs are for tropical diseases, such as African sleeping sickness and dengue fever. While patent incentives have driven commercial pharmaceutical companies to make Western health care the envy of the world, the commercial model only works if companies can sell enough patented products to cover their R&D costs and produce profits for shareholders. The model thus fails in the developing world, where few patients can afford to pay patented prices for drugs. The solution to this devastating problem, say Stephen Maurer, Arti Rai, and Andrej Sali in the premier open-access medical journal PLoS Medicine, is to adopt an “open source” approach to discovering new drugs for neglected diseases.
Link: sciencedaily.com
Category:
- Open Source
